T Cell Persistence
Showing 1 - 25 of >10,000
Determining the Mechanisms of Loss of CAR T Cell Persistence
Not yet recruiting
- Acute Lymphoblastic Leukemia With Failed Remission
- +4 more
- (no location specified)
Mar 29, 2023
COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in
Not yet recruiting
- Follicular Lymphoma
- Cellular immunity vs SARS-CoV-2
- +6 more
-
Alessandria, IT, Italy
- +13 more
Oct 10, 2023
B-cell Acute Lymphoblastic Leukemia Trial in France, United States (UCART22)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- UCART22
- CLLS52
-
Los Angeles, California
- +10 more
Sep 23, 2022
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-Cell Lymphoma, Unspecified
- CD19 CAR T-Cell(CAT19T2)
-
Guangzhou, Guangdong, China
- +1 more
Nov 4, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
Melanoma, NSCLC, Squamous Cell Carcinoma of Head and Neck Trial in United States (GEN-011, IL-2, Fludarabine)
Terminated
- Melanoma
- +8 more
- GEN-011
- +3 more
-
Gilbert, Arizona
- +7 more
Jul 13, 2022
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Pancreas Cancer, CAR-T Cell Therapy, Mesothelin Trial in Guangzhou (CAR-T cells)
Recruiting
- Pancreas Cancer
- +3 more
- CAR-T cells
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Mar 10, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer Trial in Shanghai (Fludarabine + Cyclophosphamide,
Not yet recruiting
- Cervical Cancer
- +6 more
- Fludarabine + Cyclophosphamide
- HRYZ-T101 TCR-T Cell
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 27, 2023
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)
Active, not recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Jan 18, 2023
Lymphoma Trial in Seattle (biological, other, procedure)
Not yet recruiting
- Lymphoma
- Immune Globulin Infusion (Human), 10% Solution
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 21, 2023
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,
Not yet recruiting
- Prostate Carcinoma
- +3 more
- Bendamustine
- +12 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 17, 2023
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma Trial in Barcelona (CD1a-CAR T)
Not yet recruiting
- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic T-Cell Lymphoma
- CD1a-CAR T
-
Barcelona, Spain
- +1 more
Jan 10, 2023
Bio-CAR-T BS Study
Recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
- +2 more
-
Brescia, ItalyASST Spedali Civili di Brescia
May 5, 2022
Chronic Myelomonocytic Leukemia Trial in Indianapolis (CD4CAR)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- CD4CAR
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Oct 2, 2023
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)
Active, not recruiting
- COL6A3 Positive
- +3 more
- Aldesleukin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)
Recruiting
- Hairy Cell Leukemia
- Hairy Cell Leukemia Variant
- CD22CART cell infusion
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023
